Tag Archive for: Link_TSG6

Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease

Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up completed, providing supply for planned clinical studies London, UK – 5 November 2026 – Link Biologics (“Link” or “the Company”), the biotech developing first-in-class […]

Link Biologics strengthens IP position for Link_TSG6 with US patent Notice of Allowance and University of Manchester IP assignment

Secures long‑term ownership and protection of Link_TSG6, strengthening its global IP position in key markets De‑risks development and enhances long‑term value, supporting advancement towards clinical development London, UK – 6 May 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies that have a unique combination of anti-inflammatory, tissue-protective and […]

© Optimum Strategic Communications.